Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q2 FY25 results · Jul–Sep 2024
Cohance Lifesciences reported revenue from operations of ₹257.72 crore (up 11.5% from Q2 FY24) and net profit of ₹81.98 crore (up 3.0% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 257.72 | 231.05 | +11.5% | 230.69 | +11.7% |
| Other income | 14.12 | 19.84 | −28.8% | 18.16 | −22.2% |
| Total income | 271.84 | 250.90 | +8.3% | 248.85 | +9.2% |
| Profit before tax | 99.50 | 105.41 | −5.6% | 83.08 | +19.8% |
| Net profit for the period | 81.98 | 79.56 | +3.0% | 60.76 | +34.9% |
| Attributable to shareholders of the company | 82.21 | — | — | — | — |
| EPS, basic (₹) | 3.23 | 3.13 | +3.2% | 2.39 | not comparable |
| Net margin (%) | 31.8 | 34.4 | 26.3 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 236.06 | 224.62 | +5.1% | 222.09 | +6.3% |
| Other income | 13.43 | 14.20 | −5.4% | 17.95 | −25.2% |
| Total income | 249.49 | 238.82 | +4.5% | 240.04 | +3.9% |
| Profit before tax | 100.68 | 100.57 | +0.1% | 87.39 | +15.2% |
| Net profit for the period | 76.33 | 74.73 | +2.1% | 65.08 | +17.3% |
| EPS, basic (₹) | 3.00 | 2.94 | +2.0% | 2.56 | not comparable |
| Net margin (%) | 32.3 | 33.3 | 29.3 |
Consolidated
- Filed with BSE
- 13 Nov 2024, 15:59 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2024, 15:59 IST
- Board meeting
- 12 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE